

Regulation of Endocrine Disruptors:

REACH may change, but will the science evolve?

Dr Emma Grange
emma.grange@crueltyfreeinternational.org

Who we are

Cruelty Free Europe: a new network of animal protection groups

Brussels based with a presence at the heart of EU decision-making

Working to bring animal testing to an end across Europe and beyond


Putting animals used in experiments firmly on the European political agenda

Campaigning for humane modern science and progressive legislation



Today's presentation

- What are endocrine disruptors
- Changes to REACH?
- Testing strategies
- Problems with *in vivo* testing methods
- Animal-free methods
- Our recommendations



Endocrine disruptors

Endocrine active substances

- hormone mimics
- hormone blockers
- changing hormone production and circulation



Mechanisms

- estrogen
- androgen
- thyroid
- steroidogenesis ...and more

Endocrine Disruptors cause an
adverse health outcome

Identifying EDs for humans and wildlife - not easy!

Changes to REACH?

- Calls for REACH to more fully address ED concerns
- REACH already requires a lot of test data, is more needed?
- Attempts to evaluate all substances for ED potential may **rely very heavily on studies on animals**
- Doubtful that animal data is suitable for protecting human and wildlife populations at risk



Testing strategies

- Focus on high tonnage substances?
... no, exposure is key
- Address substances one by one?
... no, mixture effects may be key
- Screen all substances, then test further if endocrine effects observed?
... no, most substances will have some degree of effect, may be no effect-free level
- Use *in vivo* tests to screen, and predict adverse health outcomes
... no, animal models may not be relevant or reliable



Testing strategies - a better approach

Testing directed by real-world **exposure**, not import and manufacture tonnages

Exposure can be:

- **Predicted** – accounting for tonnage, intrinsic properties and environmental fate (persistence, spread, accumulation)
- **Measured** - by ecological monitoring and biomonitoring. *For example:* the HMB4EU project



Problems with *in vivo* methods

- Uncertain effects relevance
- Unreliable prediction of **adverse** outcomes
- Tests not designed for endocrine disruptors
- Little or no validation

In vivo screening methods:

- Uterotrophic bioassay
- Hershberger bioassay

... reliability for detecting human-relevant effects is **not** well characterised



Problems with *in vivo* methods

In vivo tests for predicting **adverse health outcomes**:

- Repeat dose oral tox 28 day + 90 day
 - Combined toxicity and carcinogenicity studies
 - Reproduction and developmental studies
- } new or repeat studies under REACH?

Some tests updated to address endocrine disruptors
e.g. thyroid hormone measurements added

But there are concerns tests are “... ***not providing the specific information needed to assess endocrine disruption. ... at present this approach is failing.***” (CRO quoted in ChemWatch)



Non-animal methods

- *In silico* approaches and in vivo assays
- Validation work underway at ECVAM
- Advantages of NAMs:

Human and wildlife – relevant

Lower cost in the long-term

Faster, and amenable to high-throughput and automation

Ideal for addressing mixtures

- The only option for cosmetics ingredients



A testing strategy for REACH

REACH may change, but will it follow the latest science?

A solid testing strategy will be **adverse effect-driven** and will:

- Use real-world exposures to identify vulnerable populations and prioritise substances for evaluation
- Link exposure to adverse effects using epidemiological and monitoring data
- Use species-relevant non-animal methods to reveal how substances interact with the endocrine system

Our recommendations

No routine use of studies on animals to address ED concerns
yet more animal studies under REACH is not the answer

Consider real-world exposures, predicted and measured -
not import and manufacture tonnages

Use non-animal methods for human-relevant assessment of
endocrine activity

Link exposure and real-world adverse health outcomes using
biomonitoring and epidemiological data



Find out more: **Animal Testing and Endocrine Disruptors: the need for a better EU strategy**

Cruelty Free Europe Science report



Regulation of Endocrine Disruptors: REACH may change, but will the science evolve?

Dr Emma Grange

Phone: +44 (0) 207 619 6994

Address: 16a Crane Grove, London, N7 8NN, UK

Email: Emma.Grange@crueltyfreeinternational.org

Websites: www.CrueltyFreeEurope.org

